Surveyor Capital, a fundamental equities strategy of Citadel, focuses on deep fundamental research across diverse sectors including Consumer, Financials, Healthcare, Industrials, Energy & Natural Resources, and Technology, Media & Telecom. Their strategy involves developing independent views on companies, leveraging a market-neutral risk framework to minimize broad market exposures, and also acting as a seeding platform for long/short equity hedge fund managers.
Portfolio
11
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Stage Distribution
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Triana Biomedicines | Series B | $120M | Dec 2025 |
| Quanta Therapeutics | Series D | $50.7M | May 2023 |
| Arkuda Therapeutics | Series B | $64M | Feb 2022 |
| Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
| Obsidian Therapeutics | Series B | $115M | Sep 2021 |
| Gennao Bio | Series A | $40M | May 2021 |
| DTx Pharma | Series B | $100M | Mar 2021 |
| Enliven Therapeutics | Series B | $85M | Dec 2020 |
| BioShin Limited | Series A | $60M | Sep 2020 |
| Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
| ElevateBio | Series B | $170M | Mar 2020 |
Top Co-Investors
Logos Capital6 shared
Cormorant Asset Management4 shared
Janus Henderson Investors4 shared
Atlas Venture3 shared
RA Capital Management3 shared
Avidity Partners2 shared
Sofinnova Partners2 shared
Pivotal bioVenture Partners2 shared
Eli Lilly and Company2 shared
Pfizer Ventures2 shared
Deep Track Capital2 shared
Vertex Pharmaceuticals2 shared
Samsara BioCapital2 shared
Invus2 shared
OrbiMed1 shared
Longitude Capital1 shared
Mission BioCapital1 shared
Ally Bridge Group1 shared
Temasek Holdings1 shared
ArrowMark Partners1 shared
Last updated: 3 March 2026